Asia-Pacific Ophthalmology Therapeutics Market By Indication (Glaucoma, Dry Eye Syndrome, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration, Macular Edema And Allergic Conjunctivitis) By End User (Hospitals, Eye Clinics, Diagnostic Centres And Patients), And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018–2023)

Asia-Pacific Ophthalmology Therapeutics Market By Indication (Glaucoma, Dry Eye Syndrome, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration, Macular Edema And Allergic Conjunctivitis) By End User (Hospitals, Eye Clinics, Diagnostic Centres And Patients), And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018–2023)

ID: 1109 | Pages: 145 | April 2018 | Region: Asia Pacific


Asia-Pacific Ophthalmology Therapeutics Market was worth $4.89 billion in 2018 and is estimated to grow at a CAGR of 8.5%, to reach $7.35 billion by 2023. Ophthalmology is the branch of medicine that deals with the anatomy, physiology and diseases of eye. Recent advancements in genetics and stem cell biology have brought number of changes to the Ophthalmology Therapeutics Market.

Asia-Pacific Ophthalmology Therapeutics is driven by the growing prevalence for vision impairment. According to a recent update by WHO the prevalence of visual impairment is nearly 285 million globally. Of these 246 million people have moderate to severe visual impairment. South-East Asia and Western Pacific accounted for 73% of the total visual impairments. Other major factors driving the growth of market include, increasing awareness about the importance of detecting ophthalmic diseases as early as possible and the availability of efficient diagnostic tools. However, stringent regulatory framework and lack of reimbursement policies are restraining the growth of the market.

Asia-Pacific Ophthalmology Therapeutics is broadly categorized into Indication and End User. Based on indication the market is segmented into Glaucoma, Dry Eye Syndrome, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration, Macular Edema and Allergic Conjunctivitis. Glaucoma is the largest indication segment accounting for a share of approximately XX%. On the basis of End User, the market is segmented into Hospitals, Eye Clinics, Diagnostic Centres and Patients.

Geographically, Asia-Pacific Ophthalmology therapeutics market is segmented into various regions namely China, India, Japan, South Korea and Australia. Asia-Pacific is the fastest growing region with a CAGR of xx% during the forecast period. Within Asia-Pacific, Japan is the largest market for Opthalmology therapeutics accounting for a share of approximately 45% followed by China

Pfizer Inc., Allergan Inc., Alcon Inc., Merck & co. Inc., Roche, Valeant, Regeneron, Santen, Bayer, Senju, Lpath and Eye Gate Pharmaceuticals are the major companies covered in the report.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Indication                              

                                5.1.1 Glaucoma

                                5.1.2 Dry Eye Syndrome

                                5.1.3 Diabetic Retinopathy         

                                5.1.4 Retinal Vein Occlusion        

                                5.1.5 Age-Related Macular Degeneration (AMD)

                                5.1.6 Macular Edema    

                                5.1.7 Allergic Conjunctivitis         

                5.2 By End User               

                                5.2.1 Hospitals  

                                5.2.2 Eye Clinics

                                5.2.3 Diagnostic Centers              

                                5.2.4 Patients   

6. Geographical Analysis                                              

                6.1 Introduction                              

                6.2 China                            

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea               

                6.6 Australia                      

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 Allergan, Inc.                              

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Merck & Co Inc                         

                9.3 Pfizer                            

                9.4 Roche                           

                9.5 Novartis (Alcon)                       

                9.6 Valeant                        

                9.7 Regeneron                 

                9.8 Santen                         

                9.9 Bayer                            

                9.10 Senju                          

                9.11 Lpath                          

                9.12 Eye Gate Pharmaceuticals                 

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Market Outlook & Investment Opportunities                               

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Asia-Pacific Ophthalmology Therapeutics Market By Region, From 2018-2023 (USD Bllion)
  2. Asia-Pacific Ophthalmology Therapeutics Market By Indication, From 2018-2023 (USD Bllion)
  3. Asia-Pacific Glaucoma Market By Region, From 2018-2023 (USD Bllion)
  4. Asia-Pacific Dry Eye Syndrome Market By Region, From 2018-2023 (USD Bllion)
  5. Asia-Pacific Diabetic Retinopathy Market By Region, From 2018-2023 (USD Bllion)
  6. Asia-Pacific Retinal Vein Occlusion Market By Region, From 2018-2023 (USD Bllion)
  7. Asia-Pacific Age-Related Macular Degeneration (AMD) Market By Region, From 2018-2023 (USD Bllion)
  8. Asia-Pacific Macular Edema Market By Region, From 2018-2023 (USD Bllion)
  9. Asia-Pacific Allergic Conjunctivitis Market By Region, From 2018-2023 (USD Bllion)
  10. Asia-Pacific Ophthalmology Therapeutics Market By End-User, From 2018-2023 (USD Bllion)
  11. Asia-Pacific Hospitals Market By Region, From 2018-2023 (USD Bllion)
  12. Asia-Pacific Eye Clinics Market By Region, From 2018-2023 (USD Bllion)
  13. Asia-Pacific Diagnostic Centers Market By Region, From 2018-2023 (USD Bllion)
  14. Asia-Pacific Patients Market By Region, From 2018-2023 (USD Bllion)
  15. China Ophthalmology Therapeutics Market By Indication, From 2018-2023 (USD Bllion)
  16. China Ophthalmology Therapeutics Market By End-User, From 2018-2023 (USD Bllion)
  17. India Ophthalmology Therapeutics Market By Indication, From 2018-2023 (USD Bllion)
  18. India Ophthalmology Therapeutics Market By End-User, From 2018-2023 (USD Bllion)
  19. Japan Ophthalmology Therapeutics Market By Indication, From 2018-2023 (USD Bllion)
  20. Japan Ophthalmology Therapeutics Market By End-User, From 2018-2023 (USD Bllion)
  21. South Korea Ophthalmology Therapeutics Market By Indication, From 2018-2023 (USD Bllion)
  22. South Korea Ophthalmology Therapeutics Market By End-User, From 2018-2023 (USD Bllion)
  23. Australia Ophthalmology Therapeutics Market By Indication, From 2018-2023 (USD Bllion)
  24. Australia Ophthalmology Therapeutics Market By End-User, From 2018-2023 (USD Bllion)
Middle-East & Africa Cardiovascular Therapeutic Drugs By Disease (Arteriosclerosis, Cardiac Arrhythmias, Myocardial Infarction, Acute Coronary Syndrome, Peripheral Artery Disease, Coronary Artery Disease, Hypertensi...
Middle East And Africa Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail...
Latin America Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmaci...
Asia Pacific Clostridium Botulinum Market By Product (botulinum Toxin Type A And Botulinum Toxin Type B), By End User (aesthetic And Therapeutics), By Distribution Channel (hospitals, Clinics And Retail Pharmacies) ...
Europe Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmacies) And...
North America Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmaci...
Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmacies) And By Reg...
The Dental Bone Graft Substitutes Market Is Predicted To Reach USD 664.3 Million With A CAGR Of 9.8% According To Market Data Forecast Report....
Middle East And Africa Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal D...
Latin America Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Reg...
Asia-Pacific Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Rege...
Europe Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Regenerati...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2018 Market Data Forecast
All Rights Reserved.